Table 4.
Probability of Attending a Given Follow-Up Visit by 5-Year Interval Since Completion of Treatment and Selected Demographic and Clinical Characteristics
| 1–5 years | 6–10 years | 11–15 years | 16–20 years | 21–25 years | 26+ years | |
|---|---|---|---|---|---|---|
| Age (years) | ||||||
| 0–4 | 93.6 (90.9–95.6) | 74.4 (70.0–78.3) | 55.9 (50.9–60.7) | 32.7 (28.2–37.6) | 24.8 (20.3–29.9) | 12.7 (9.9–16.1) |
| 5–9 | 92.4 (89.7–94.5) | 72.6 (68.2–76.5) | 51.6 (46.5–56.7) | 39.8 (34.1–45.7) | 27.1 (21.4–33.5) | 16.6 (12.4–21.9) |
| 10–15 | 88.2 (85.2–90.7) | 66.8 (62.6–70.8) | 42.5 (37.9–47.2) | 31.6 (27.0–36.7) | 31.4 (26.0–37.3) | 21.0 (16.9–25.8) |
| 15–21 | 88.5 (85.0–91.3) | 58.7 (53.7–63.6) | 40.3 (34.7–46.1) | 36.6 (30.7–43.1) | 38.1 (31.0–45.7) | 38.1 (31.7–44.9) |
| Gender | ||||||
| Male | 90.6 (88.6–92.3) | 66.9 (63.7–69.8) | 44.9 (41.4–48.4) | 31.2 (27.8–34.8) | 30.3 (26.4–34.4) | 22.3 (19.4–25.5) |
| Female | 90.7 (88.6–92.5) | 70.0 (66.8–73.0) | 51.2 (47.5–54.8) | 38.9 (34.9–43.0) | 28.4 (24.4–32.9) | 16.7 (13.7–20.2) |
| Race | ||||||
| Caucasian | 91.5 (90.1–92.8) | 69.8 (67.4–72.0) | 50.5 (47.8–53.2) | 36.2 (33.5–39.1) | 30.5 (27.5–33.6) | 20.8 (18.6–23.3) |
| African American | 84.1 (77.2–89.2) | 56.2 (47.5–64.5) | 22.7 (15.8–31.5) | 15.8 (9.2–25.8) | 15.8 (7.2–31.1) | 2.9 (0.4–17.9) |
| Other | 81.8 (69.4–89.9) | 54.5 (39.8–68.5) | 23.3 (11.5–41.6) | 16.7 (5.4–41.0) | 0.0 (0.0–100.0) | 0.0 (0.0–100.0) |
| Surgery | ||||||
| No | 92.0 (90.0–93.6) | 72.1 (69.0–75.0) | 52.5 (48.8–56.2) | 40.9 (37.0–44.9) | 33.7 (29.5–38.2) | 18.8 (15.7–22.2) |
| Yes | 89.3 (87.1–91.1) | 64.7 (61.4–67.8) | 43.9 (40.4–47.4) | 28.9 (25.5–32.6) | 25.4 (21.7–29.4) | 21.0 (18.1–24.3) |
| Chemotherapy | ||||||
| No | 78.3 (70.0–84.8) | 54.7 (45.6–63.5) | 36.2 (27.6–45.8) | 21.7 (14.4–31.4) | 16.7 (9.9–26.7) | 9.9 (5.7–16.7) |
| Yes | 91.5 (90.1–92.7) | 69.3 (67.1–71.5) | 48.8 (46.2–51.5) | 35.7 (33.0–38.6) | 30.6 (27.6–33.7) | 21.1 (18.8–23.6) |
| Radiation | ||||||
| No | 91.5 (89.6–93.1) | 69.5 (66.5–72.4) | 47.5 (44.0–50.9) | 35.3 (31.7–39.0) | 29.3 (25.5–33.4) | 13.5 (11.1–16.4) |
| Yes | 89.7 (87.4–91.5) | 67.0 (63.7–70.2) | 48.5 (44.7–52.2) | 34.0 (30.2–38.1) | 29.6 (25.4–34.1) | 27.6 (24.1–31.5) |
| Decade | ||||||
| 1960/70s | 90.8 (87.7–93.2) | 70.9 (66.5–75.0) | 55.4 (50.7–60.0) | 43.6 (39.0–48.3) | 33.3 (29.0–37.8) | 18.3 (16.0–20.9) |
| 1980s | 94.1 (91.6–95.9) | 72.2 (68.0–76.1) | 46.9 (42.5–51.5) | 33.2 (29.1–37.6) | 27.3 (23.3–31.6) | 25.8 (21.0–31.3) |
| 1990s | 89.7 (86.8–92.0) | 62.1 (57.9–66.1) | 40.6 (36.4–45.0) | 24.7 (20.3–29.7) | 15.4 (7.9–27.9) | |
| 2000s | 87.6 (83.9–90.5) | 69.7 (64.3–74.7) | 62.3 (49.6–73.5) | |||
| Diagnosis | ||||||
| Leukemia | 94.1 (91.8–95.7) | 76.7 (72.9–80.1) | 59.5 (55.0–63.9) | 48.8 (44.1–53.6) | 39.9 (34.9–45.1) | 19.7 (16.4–23.5) |
| Lymphoma | 93.4 (91.1–95.1) | 69.9 (65.9–73.5) | 43.4 (38.8–48.1) | 27.9 (23.4–32.8) | 26.4 (21.3–32.2) | 29.3 (24.3–34.8) |
| CNS cancer | 80.0 (72.0–86.1) | 41.6 (33.3–50.4) | 28.7 (20.9–38.0) | 14.3 (8.1–24.0) | 8.0 (3.0–19.5) | 0.0 (0.0–100.0) |
| Sarcoma | 85.6 (81.0–89.2) | 62.9 (56.9–68.5) | 43.0 (36.8–49.4) | 31.1 (25.0–38.0) | 26.8 (20.1–34.7) | 19.7 (15.0–25.6) |
| Other cancer | 87.6 (83.2–91.0) | 66.2 (60.2–71.7) | 47.1 (40.9–53.4) | 27.4 (21.5–34.2) | 18.6 (13.1–25.8) | 9.6 (6.2–14.7) |
Numbers in parentheses identify 95% confidence interval for each estimate.